Therapeutic epilepsy research: From pharmacological rationale to focal adenosine augmentation

Biochemical Pharmacology

Volumn 78, Issue 12, 2009, Pages 1428-1437

  Boison, Detlev ^a   Stewart, Kerry Ann ^a  

^a LEGACY RESEARCH   (United States)

Author keywords

Adenosine; Adenosine receptor; Epilepsy; Epileptogenesis; Focal drug delivery

Indexed keywords

ABT 702; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE KINASE; ADENOSINE KINASE INHIBITOR; ADENOSINE TRIPHOSPHATE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; LORAZEPAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PARVOVIRUS VECTOR; PHENOBARBITAL; PHENYTOIN; PREGABALIN; TARIQUIDAR; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN;

ARTICLE; ASTROCYTE; ASTROCYTOSIS; BRAIN BLOOD FLOW; BRAIN DEPTH STIMULATION; BRAIN SURGERY; CHRONIC PAIN; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; ENZYME INHIBITION; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; EX VIVO GENE TRANSFER; HUMAN; NERVE CELL NETWORK; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN FUNCTION; STEM CELL TRANSPLANTATION; TEMPORAL LOBE EPILEPSY; THERAPY RESISTANCE; VIRAL GENE THERAPY;

EID: 70349984540     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.08.005     Document Type: Note

References (75)

1. Nadkarni S., LaJoie J., and Devinsky O. Current treatments of epilepsy. Neurology 64 (2005) S2-S11
2. Luna-Tortos C., Fedrowitz M., and Loscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 55 (2008) 1364-1375
3. Hughes J.R. One of the hottest topics in epileptology: ABC proteins. Their inhibition may be the future for patients with intractable seizures. Neurol Res 30 (2008) 920-925
4. Verkhratsky A. Neuronismo y reticulismo: neuronal-glial circuits unify the reticular and neuronal theories of brain organization. Acta Physiol (Oxf) 195 (2009) 111-122
5. Halassa M.M., Fellin T., and Haydon P.G. The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med 13 (2007) 54-63
6. Oberheim N.A., Tian G.F., Han X., Peng W., Takano T., Ransom B., et al. Loss of astrocytic domain organization in the epileptic brain. J Neurosci 28 (2008) 3264-3276
7. Haydon P.G., and Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev 86 (2006) 1009-1031
8. Tian G.F., Azmi H., Takano T., Xu Q.W., Peng W.G., Lin J., et al. An astrocytic basis of epilepsy. Nat Med 11 (2005) 973-981
9. Wetherington J., Serrano G., and Dingledine R. Astrocytes in the epileptic brain. Neuron 58 (2008) 168-178
10. Rouach N., Koulakoff A., Abudara V., Willecke K., and Giaume C. Astroglial metabolic networks sustain hippocampal synaptic transmission. Science 322 (2008) 1551-1555
11. Ravizza T., Gagliardi B., Noe F., Boer K., Aronica E., and Vezzani A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis 29 (2008) 142-160
12. Pascual O., Casper K.B., Kubera C., Zhang J., Revilla-Sanchez R., Sul J.Y., et al. Astrocytic purinergic signaling coordinates synaptic networks. Science 310 (2005) 113-116
13. Boison D. The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol 84 (2008) 249-262
14. North R.A., and Verkhratsky A. Purinergic transmission in the central nervous system. Pflugers Arch 452 (2006) 479-485
15. Schipke C.G., and Kettenmann H. Astrocyte responses to neuronal activity. Glia 47 (2004) 226-232
16. Pocock J.M., and Kettenmann H. Neurotransmitter receptors on microglia. Trends Neurosci 30 (2007) 527-535
17. Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov 7 (2008) 575-590
18. During M.J., and Spencer D.D. Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann Neurol 32 (1992) 618-624
19. Boison D. Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies. Neuroscientist 11 (2005) 25-36
20. Newby A.C., Worku Y., and Holmquist C.A. Adenosine formation. Evidence for a direct biochemical link with energy metabolism. Adv Myocardiol 6 (1985) 273-284
21. Schrader J., Wahl M., Kuschinsky W., and Kreutzberg G.W. Increase of adenosine content in cerebral cortex of the cat during bicuculline-induced seizure. Pflugers Arch 387 (1980) 245-251
22. Dragunow M., and Goddard G.V. Adenosine modulation of amygdala kindling. Exp Neurol 84 (1984) 654-665
23. Cristalli G., Lambertucci C., Marucci G., Volpini R., and Dal Ben D. A(2A) adenosine receptor and its modulators: Overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists. Curr Pharm Des 14 (2008) 1525-1552
24. Benarroch E.E. Adenosine and its receptors: multiple modulatory functions and potential therapeutic targets for neurologic disease. Neurology 70 (2008) 231-236
25. Jacobson K.A., and Gao Z.G. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5 (2006) 247-264
26. Kowaluk E.A., and Jarvis M.F. Therapeutic potential of adenosine kinase inhibitors. Expert Opin Investig Drugs 9 (2000) 551-564
27. McGaraughty S., Cowart M., Jarvis M.F., and Berman R.F. Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. Curr Top Med Chem 5 (2005) 43-58
28. Lado F.A., and Moshe S.L. How do seizures stop?. Epilepsia 49 (2008) 1651-1664
29. 1 receptors are crucial in keeping an epileptic focus localized. Exp Neurol 200 (2006) 184-190
30. Fredholm B.B., Ijzerman A.P., Jacobson K.A., Klotz K.N., and Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53 (2001) 527-552
31. Li T., Lan J.Q., Fredholm B.B., Simon R.P., and Boison D. Adenosine dysfunction in astrogliosis: cause for seizure generation?. Neuron Glia Biol 3 (2007) 353-366
32. Kochanek P.M., Vagni V.A., Janesko K.L., Washington C.B., Crumrine P.K., Garman R.H., et al. Adenosine A1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. J Cereb Blood Flow Metab 26 (2006) 565-575
33. Cunha R.A. Different cellular sources and different roles of adenosine: A(1) receptor-mediated inhibition through astrocytic-driven volume transmission and synapse-restricted A(2A) receptor-mediated facilitation of plasticity. Neurochem Int 52 (2008) 65-72
34. Arch J.R., and Newsholme E.A. Activities and some properties of 5′-nucleotidase, adenosine kinase and adenosine deaminase in tissues from vertebrates and invertebrates in relation to the control of the concentration and the physiological role of adenosine. Biochem J 174 (1978) 965-977
35. Li T., Ren G., Lusardi T., Wilz A., Lan J.Q., Iwasato T., et al. Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. J Clin Invest 118 (2008) 571-582
36. Anschel D.J., Ortega E.L., Kraus A.C., and Fisher R.S. Focally injected adenosine prevents seizures in the rat. Exp Neurol 190 (2004) 544-547
37. Spedding M., and Williams M. Developments in purine and pyridimidine receptor-based therapeutics. Drug Dev Res 39 (1996) 436-441
38. Williams M. Developments in P2 receptor targeted therapeutics. Prog Brain Res 120 (1999) 93-106
39. Williams M., and Jarvis M.F. Purinergic and pyrimidinergic receptors as potential drug targets. Biochem Pharmacol 59 (2000) 1173-1185
40. 1 receptor activation in a mouse model of pharmacoresistant epilepsy. Epilepsia 44 (2003) 877-885
41. Monopoli A., Conti A., Dionisotti S., Casati C., Camaioni E., Cristalli G., et al. Pharmacology of the highly selective A1 adenosine receptor agonist 2-chloro-N6-cyclopentyladenosine. Arzneimittelforschung 44 (1994) 1305-1312
42. Kowaluk E.A., Mikusa J., Wismer C.T., Zhu C.Z., Schweitzer E., Lynch J.J., et al. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat. J Pharmacol Exp Ther 295 (2000) 1165-1174
43. Jarvis M.F., Yu H., Kohlhaas K., Alexander K., Lee C.H., Jiang M., et al. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. I. In vitro characterization and acute antinociceptive effects in the mouse. J Pharmacol Exp Ther 295 (2000) 1156-1164
44. Suzuki R., Stanfa L.C., Kowaluk E.A., Williams M., Jarvis M.F., and Dickenson A.H. The effect of ABT-702, a novel adenosine kinase inhibitor, on the responses of spinal neurones following carrageenan inflammation and peripheral nerve injury. Br J Pharmacol 132 (2001) 1615-1623
45. Gouder N., Scheurer L., Fritschy J.-M., and Boison D. Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis. J Neurosci 24 (2004) 692-701
46. McGaraughty S., and Jarvis M.F. Purinergic control of neuropathic pain. Drug Dev Res 67 (2006) 376-388
47. Jarvis M.F., Mikusa J., Chu K.L., Wismer C.T., Honore P., Kowaluk E.A., et al. Comparison of the ability of adenosine kinase inhibitors and adenosine receptor agonists to attenuate thermal hyperalgesia and reduce motor performance in rats. Pharmacol Biochem Behav 73 (2002) 573-581
48. Boison D., Scheurer L., Zumsteg V., Rülicke T., Litynski P., Fowler B., et al. Neonatal hepatic steatosis by disruption of the adenosine kinase gene. Proc Natl Acad Sci USA 99 (2002) 6985-6990
49. Mato J.M., Martinez-Chantar M.L., and Lu S.C. Methionine metabolism and liver disease. Annu Rev Nutr 28 (2008) 273-293
50. Erion M.D., Wiesner J.B., Rosengren S., Ugarkar B.G., Boyer S.H., and Tsuchiya M. Therapeutic potential of adenosine kinase inhibitors as analgesic agents. Drug Dev Res 50 (2000) S14-S16
51. Huber A., Padrun V., Deglon N., Aebischer P., Mohler H., and Boison D. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc Natl Acad Sci USA 98 (2001) 7611-7616
52. Horan R.L., Antle K., Collette A.L., Wang Y., Huang J., Moreau J.E., et al. In vitro degradation of silk fibroin. Biomaterials 26 (2005) 3385-3393
53. Wilz A., Pritchard E.M., Li T., Lan J.Q., Kaplan D.L., and Boison D. Silk polymer-based adenosine release: therapeutic potential for epilepsy. Biomaterials 29 (2008) 3609-3616
54. Aebischer P., Tresco P.A., Winn S.R., Greene L.A., and Jaeger C.B. Long-term cross-species brain transplantation of a polymer-encapsulated dopamine-secreting cell line. Exp Neurol 111 (1991) 269-275
55. Schneider B.L., Schwenter F., Pralong W.F., and Aebischer P. Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery. Mol Ther 7 (2003) 506-514
56. 1 receptor desensitization after focal long-term delivery of adenosine by encapsulated myoblasts. Exp Neurol 193 (2005) 53-64
57. Boison D. Cell and gene therapies for refractory epilepsy. Curr Neuropharmacol 5 (2007) 115-125
58. Loscher W., Gernert M., and Heinemann U. Cell and gene therapies in epilepsy - promising avenues or blind alleys?. Trends Neurosci 31 (2008) 62-73
59. Shetty A.K., and Hattiangady B. Concise review: prospects of stem cell therapy for temporal lobe epilepsy. Stem Cells 25 (2007) 2396-2407
60. Fedele D.E., Koch P., Brüstle O., Scheurer L., Simpson E.M., Mohler H., et al. Engineering embryonic stem cell derived glia for adenosine delivery. Neurosci Lett 370 (2004) 160-165
61. Li T., Steinbeck J.A., Lusardi T., Koch P., Lan J.Q., Wilz A., et al. Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. Brain 130 (2007) 1276-1288
62. Li J.Y., Christophersen N.S., Hall V., Soulet D., and Brundin P. Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends Neurosci 31 (2008) 146-153
63. Ren G., Li T., Lan J.Q., Wilz A., Simon R.P., and Boison D. Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control. Exp Neurol 208 (2007) 26-37
64. Li T., Ren G., Kaplan D.L., and Boison D. Human mesenchymal stem cell grafts engineered to release adenosine reduce chronic seizures in a mouse model of CA3-selective epileptogenesis. Epilepsy Res 84 (2009) 238-241
65. Palella T.D., Hidaka Y., Silverman L.J., Levine M., Glorioso J., and Kelley W.N. Expression of human HPRT mRNA in brains of mice infected with a recombinant herpes simplex virus-1 vector. Gene 80 (1989) 137-144
66. Freese A., Kaplitt M.G., Oconnor W.M., Abbey M., Langer D., Leone P., et al. Direct gene transfer into human epileptogenic hippocampal tissue with an adeno-associated virus vector - implications for a gene therapy approach to epilepsy. Epilepsia 38 (1997) 759-766
67. Noe F., Frasca A., Balducci C., Carli M., Sperk G., Ferraguti F., et al. Neuropeptide Y overexpression using recombinant adeno-associated viral vectors. Neurotherapeutics 6 (2009) 300-306
68. Kaplitt M.G., Feigin A., Tang C., Fitzsimons H.L., Mattis P., Lawlor P.A., et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369 (2007) 2097-2105
69. Marks Jr. W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 7 (2008) 400-408
70. Szybala C., Pritchard E.M., Wilz A., Kaplan D.L., and Boison D. Antiepileptic effects of silk-polymer based adenosine release in kindled rats. Exp Neurol 219 (2009) 126-135
71. Silver J.M., Shin C., and McNamara J.O. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilespy. Ann Neurol 29 (1991) 356-363
72. Boon P., Raedt R., de Herdt V., Wyckhuys T., and Vonck K. Electrical stimulation for the treatment of epilepsy. Neurotherapeutics 6 (2009) 218-227
73. Freeman J.M., Vining E.P., Kossoff E.H., Pyzik P.L., Ye X., and Goodman S.N. A blinded, crossover study of the efficacy of the ketogenic diet. Epilepsia 50 (2009) 322-325
74. Masino S.A., and Geiger J.D. Are purines mediators of the anticonvulsant/neuroprotective effects of ketogenic diets?. Trends Neurosci 31 (2008) 273-278
75. Eisenach J.C., Hood D.D., and Curry R. Phase I safety assessment of intrathecal injection of an American formulation of adenosine in humans. Anesthesiology 96 (2002) 24-28